Evidence map›Paper›PMID 27759712›Full record

ArticlePancreas2017

Peptide Receptor Radionuclide Therapy Outcomes in a North American Cohort With Metastatic Well-Differentiated Neuroendocrine Tumors.

Nancy Sharma, Boris G Naraev, Eric G Engelman, M Bridget Zimmerman, David L Bushnell, Thomas M OʼDorisio, M Sue OʼDorisio, Yusuf Menda, Jan Müller-Brand, James R Howe and 1 more

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Pancreas, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.

0numbers the graph read from it
0cells of the map it votes in
26citing papers in PubMed
1.9field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

26 citing papers in PubMed, 49 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Review
  11. Review
  12. PRRT: identikit of the perfect patient.Reviews in endocrine & metabolic disorders · 2021
    Review
  13. Review
  14. Article
  15. Review
  16. Multiple endocrine neoplasia 1: a broad overview.Therapeutic advances in chronic disease · 2021
    Review
  17. Article
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 1 country.

Nancy SharmaFrom the *Division of Hematology, Oncology, and Bone and Marrow Transplantation and the Holden Comprehensive Cancer Center, University of Iowa Hospitals and Clinics, Iowa City, IA; †Banner MD Anderson Cancer Center, Gilbert, AZ; ‡Medical Associates Clinic, Dubuque; and §Department of Biostatistics, College of Public Health, University of Iowa; ∥Department of Radiology, University of Iowa Hospitals and Clinics; ¶Iowa City Veterans Administration Medical Center; #Division of Endocrinology and Metabolism and the Holden Comprehensive Cancer Center, University of Iowa Hospitals and Clinics; and **Department of Pediatrics, University of Iowa Hospitals and Clinics, Iowa City, IA; ††Institute of Nuclear Medicine, University Hospital Basel, Basel, Switzerland; ‡‡Division of Surgical Oncology, University of Iowa Hospitals and Clinics, Iowa City, IA; and §§Division of Medical Oncology, Mayo Clinic Rochester, Rochester, MN.
Boris G Naraev
Eric G Engelman
M Bridget Zimmerman
David L Bushnell
Thomas M OʼDorisio
M Sue OʼDorisio
Yusuf Menda
Jan Müller-Brand
James R Howe
Thorvardur R Halfdanarson
Banner MD Anderson Cancer CenterUniversity of Iowa Hospitals and Clinics · USMayo Clinic · US

Funding

Viral VectorP30CA086862 · NCI · UNIVERSITY OF IOWA · PI Christopher K Laubenthal · 2000 to 2026
$70.0M
Project 4: New Approaches to Improving the Effectiveness of Radionuclide Targeted Treatments in Neuroendocrine TumorsP50CA174521 · NCI · UNIVERSITY OF IOWA · PI ODORISIO, THOMAS · 2015 to 2021
$13.2M
NCI NIH HHS P50 CA174521
6 · The paper itself

Abstract

objectivesThe objective of this study was to describe the outcomes of patients in the University of Iowa Neuroendocrine Tumor (NET) Database treated with peptide receptor radionuclide therapy (PRRT).

methodsOne hundred thirty-five patients from the University of Iowa NET Database who received PRRT were analyzed, their characteristics were described, and survival was calculated.

resultsThe median age at diagnosis was 51 years, and 64% were men. The primary tumor was located in the small bowel (SBNET) in 37.8%, in the pancreas (PNET) in 26.0%, in the lung in 13.3%, in unknown primary in 9.6%, and in other sites in 13.3%. A radiographic response of any magnitude was observed in 65.8%, 11.1% had a mixed response, and 15.4% showed progression. The overall survival (OS) from the first PRRT was 40 months, and the median time to progression was 23.9 months. Higher pretreatment chromogranin A and pancreastatin levels predicted inferior OS.

conclusionsPeptide receptor radionuclide therapy resulted in a relatively long OS and time to progression in heavily pretreated North American patients with advanced NETs. Elevated pretreatment chromogranin A and pancreastatin predicted shorter OS after therapy. Peptide receptor radionuclide therapy is a valuable treatment option in patients with advanced NETs, especially SBNETS.

Indexed as

AdolescentAdultAgedCohort StudiesFemaleHumansIowaKaplan-Meier EstimateMaleMiddle AgedNeoplasm MetastasisNeuroendocrine TumorsOctreotideRadiopharmaceuticalsYoung AdultOctreotideRadiopharmaceuticals

Identifiers

PMID27759712
PMCPMC5595066
OpenAlexW2533458501

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.